IBVape Response to surgeon general’s report on e cigarettes and Why IBVape Urges Evidence Based Dialogue

In light of recent national health communications and summaries related to vaping, IBVape offers a reasoned and evidence-focused commentary that seeks to promote clarity, reduce misinformation, and encourage balanced policy debate. This piece outlines how product stakeholders, clinicians, policymakers, and consumers can engage in an evidence-based dialogue about the findings and claims that appear in the surgeon general’s report on e cigarettes, while also articulating IBVape’s commitment to transparent information sharing and responsible industry conduct.

Why an evidence-centered conversation matters

Public health guidance benefits when it is rooted in high-quality evidence, transparent methodology, and careful distinction between absolute and relative risks. Too often, nuance is lost in headlines and summaries. IBVape believes that thoughtful discussion of nicotine delivery products must acknowledge complex factors such as population-level effects, differential risks for adult smokers versus youth never-smokers, product variability, and the changing science around long-term outcomes. Reframing the discourse toward verification, reproducibility, and harm minimization will improve public trust and lead to better outcomes.

Key messages IBVape urges stakeholders to consider

• Contextualize risk: Not all nicotine products carry identical harm profiles. While no product is risk-free, comparative risk assessment is essential.
• Differentiate user groups: Adults attempting to quit combusted tobacco often have different risk-benefit considerations than youth who are initiating nicotine use.
• Prioritize evidence quality: Observational signals, short-term biomarker changes, and modeling studies should be interpreted alongside randomized controlled trials and meta-analyses where available.
• Support targeted interventions: Policies must balance youth prevention with harm reduction opportunities for current smokers.

How IBVape reads the main assertions in the latest reports

When independent public health reviews, including the surgeon general’s report on e cigarettes, raise concerns about nicotine exposure, youth initiation, or product safety, IBVape carefully reviews the citations, methods, and the distinction between correlation and causation. Many reports compile a wide body of literature, and IBVape endorses continued research investment into longitudinal studies, standardized exposure assessment, and clinical endpoints. At the same time, IBVape highlights where meta-analytic consistency exists in favor of harm reduction potential for adult smokers who switch from combusted tobacco to lower-risk nicotine delivery systems.

Research gaps that require attention

To improve future public health recommendations, IBVape supports efforts to close several research gaps: accurate measurement of long-term respiratory and cardiovascular outcomes among exclusive users; standardized reporting of product composition and emissions; independent replication of biomarker studies; and age-stratified studies that separate experimentation from sustained use. Greater transparency in study funding, methods, and raw data sharing would accelerate consensus building and reduce polarized interpretations.

Practical steps for regulators and health communicators

Policymakers can adopt specific practices that align with evidence-based public health goals:

1. Mandate data transparency: Encourage or require submission of standardized product testing and emissions data from manufacturers and independent laboratories.
2. Use proportionate regulation: Apply stricter controls on youth-targeted marketing and flavored products while preserving pathways for adult smokers to access effective alternatives.
3. Invest in cessation services: Support integration of proven cessation counseling with access to lower-risk nicotine products where clinically appropriate.
4. Strengthen surveillance: Implement robust surveillance systems to track patterns of initiation, switching, and dual use across demographic groups.

IBVape strongly advocates for regulatory approaches that reduce net population harm rather than implementing one-size-fits-all prohibitions that may inadvertently maintain higher rates of cigarette smoking.

Communication strategies for public trust

Health messages must be accurate, transparent, and offer clear guidance. Simple, binary claims rarely capture the complexity of nicotine product risks. Messages should:

• State knowns and unknowns explicitly.
• Differentiate between short-term findings and long-term evidence.
• Offer actionable guidance for specific audiences (e.g., “if you are an adult smoker, speak to a clinician about cessation options”).

IBVape invests in educational resources that clarify product characteristics, proper device usage, and battery safety, and supports collaborations with independent public health groups to co-create content that reaches diverse populations.

The role of industry in promoting safer outcomes

As a participant in the marketplace, IBVape recognizes responsibilities that go beyond commercial interest. The company supports strict quality control, adverse event reporting, and voluntary initiatives to restrict youth access. IBVape promotes product stewardship principles: rigorous manufacturing standards, clear ingredient disclosure, and consumer education campaigns emphasizing legal age purchase and safe operation.

By embedding consumer safety into product design and commercial practices, IBVape seeks to reduce accidental injuries and discourage underage initiation.

Evidence-based policy options IBVape supports

Some policy measures that align with IBVape’s evidence-based stance include:

• Licensing and age verification mechanisms that are enforceable and technologically robust.
• Packaging standards that include accurate nicotine content and clear safety warnings without over-sensationalizing risks.
• Targeted flavor policies that consider adult cessation benefits while limiting youth appeal, implemented through careful market analysis.
• Research funding allotted for independent longitudinal studies and biomarker research to clarify long-term impacts.

How clinicians can use current evidence

Clinicians benefit from balanced guidance: acknowledge that while abstinence from all nicotine is ideal for non-users, for adult smokers who cannot quit cigarettes, switching to lower-risk nicotine delivery systems may reduce exposure to certain harmful combustion products. Healthcare professionals should be equipped with up-to-date, unbiased summaries of the literature to counsel patients effectively, including behavioral support and monitoring when recommending alternatives.

Addressing common misunderstandings

There are several recurring misconceptions in media coverage and public discourse:

• Misconception: All vaping is as harmful as smoking. Reality: Current evidence indicates differential risk profiles between combusted tobacco and aerosolized nicotine delivery in many exposure metrics.
• Misconception: Flavored products exist solely to attract youth. Reality: Many adult smokers cite flavors as a reason for switching and maintaining abstinence from cigarettes; policy must balance both concerns.
• Misconception: The presence of nicotine equates to acute toxicity in casual use. Reality: Nicotine carries dependency risk and cardiovascular effects at high doses, but acute toxicity is uncommon in typical consumer use when devices and liquid concentrations are used as intended. Safe packaging and education further mitigate accidental exposures.

IBVape commitments to research and collaboration

To support a constructive ecosystem, IBVape pledges to fund independent research, collaborate with academic institutions, and share non-proprietary emissions data with regulators and researchers. The company invites multi-stakeholder dialogues that include public health experts, clinicians, consumer advocates, and regulators, with the goal of designing policies that reflect evolving evidence and reduce tobacco-related disease burden.

Monitoring and evaluation

Robust monitoring frameworks help determine whether policies achieve intended population health outcomes. IBVape recommends mixed-method approaches combining quantitative surveillance, qualitative community feedback, and independent audits of compliance with age-restriction laws and product standards.

Practical recommendations for consumers

For adults currently using combustible tobacco and considering alternatives: consult a healthcare provider, review product ingredient transparency, choose products from manufacturers who adhere to quality standards, and access cessation support services. For parents and caregivers: secure devices and e-liquids away from children, enable parental controls where available, and discuss the known risks and reasons for legal-age purchasing rules.

Conclusion: balancing caution and opportunity

The dialogue surrounding the surgeon general’s report on e cigarettes and similar public health reviews often centers on risk communication. IBVape’s core message is that public health progress depends on embracing high-quality evidence, acknowledging uncertainties, preserving pathways for adult harm reduction, and implementing targeted youth protection measures. Only a measured, evidence-first approach will produce policies that reduce net harm and improve population health outcomes.